Immunotherapy targeting immune checkpoint blockades such as PD‐L1 and TIGIT has produced some promising results in treating AE.[22, 64, 65] Recently, neutrophil has been identified as a potential target in immunotherapy for cancers.[54] Whether the interventions against neutrophils could benefit AE treatment may be worth exploring. The gene discussed is TIGIT; the disease is cancer.